An Agent-Based Model of Solid Tumor Progression

Simulation techniques used to generate complex biological models are recognized as promising research tools especially in oncology. Here, we present a computer simulation model that uses an agent-based system to mimic the development and progression of solid tumors. The model includes influences of the tumor's own features, the host immune response and level of tumor vascularization. The interactions among those complex systems were modeled using a multi-agent modeling environment provided by Netlogo. The model consists of a hierarchy of active objects including cancer cells, immune cells, and energy availability. The simulations conducted indicate the key importance of the nutrient needs of the tumor cells and of the initial responsiveness of the immune system in the tumor progression. Furthermore, the model strongly suggests that immunotherapy treatment will be efficient in individual with sustained immune responsiveness.

[1]  Daniel G. Mallet,et al.  A cellular automata model of tumorimmune system interactions , 2006 .

[2]  S. McDougall,et al.  Mathematical modeling of tumor-induced angiogenesis. , 2006, Annual review of biomedical engineering.

[3]  Masahiro Takada,et al.  Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo , 2007, Breast Cancer Research and Treatment.

[4]  H. Othmer,et al.  Mathematical modeling of tumor-induced angiogenesis , 2004, Journal of mathematical biology.

[5]  Byungkook Lee,et al.  Modeling Recombinant Immunotoxin Efficacies in Solid Tumors , 2008, Annals of Biomedical Engineering.

[6]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[7]  T. Deisboeck,et al.  Development of a three-dimensional multiscale agent-based tumor model: simulating gene-protein interaction profiles, cell phenotypes and multicellular patterns in brain cancer. , 2006, Journal of theoretical biology.

[8]  L. D. de Pillis,et al.  A cellular automata model of tumor-immune system interactions. , 2006, Journal of theoretical biology.

[9]  S. Kim-Schulze,et al.  The tumour microenvironment and implications for cancer immunotherapy , 2006, Expert opinion on biological therapy.

[10]  D. G. Mallet,et al.  Spatial tumor-immune modeling , 2006 .

[11]  A. Radunskaya,et al.  Mixed Immunotherapy and Chemotherapy of Tumors: Modeling, Applications and Biological Interpretations , 2022 .

[12]  George D Geromichalos Importance of molecular computer modeling in anticancer drug development. , 2007, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[13]  Tutut Herawan,et al.  Computational and mathematical methods in medicine. , 2006, Computational and mathematical methods in medicine.

[14]  Wei Zhao,et al.  Mutations of PIK3CA in gastric adenocarcinoma , 2005, BMC Cancer.

[15]  L. G. de Pillisa,et al.  Mixed immunotherapy and chemotherapy of tumors : modeling , applications and biological interpretations , 2006 .

[16]  Salvatore Torquato,et al.  Modeling the effects of vasculature evolution on early brain tumor growth. , 2006, Journal of theoretical biology.

[17]  N. Komarova Mathematical modeling of tumorigenesis: mission possible , 2005, Current opinion in oncology.

[18]  P. Neeson,et al.  Effects of the Tumor Microenvironment on the Efficacy of Tumor Immunotherapy , 2006, Immunological investigations.

[19]  M Kardar,et al.  Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies , 2007, Physics in medicine and biology.

[20]  M. J. Tevethia,et al.  Mice with Spontaneous Pancreatic Cancer Naturally Develop MUC-1-Specific CTLs That Eradicate Tumors When Adoptively Transferred1 , 2000, The Journal of Immunology.

[21]  Barbara Franceschini,et al.  Quantitative evaluation and modeling of two-dimensional neovascular network complexity: the surface fractal dimension , 2005, BMC Cancer.

[22]  C. A. Condat,et al.  A multilevel approach to cancer growth modeling. , 2008, Journal of theoretical biology.

[23]  Marilena Loizidou,et al.  Endothelin-1 and angiogenesis in cancer. , 2005, Current vascular pharmacology.

[24]  Marco A J Iafolla,et al.  Extracting biochemical parameters for cellular modeling: A mean-field approach. , 2006, The journal of physical chemistry. B.

[25]  T. Secomb,et al.  A theoretical model for oxygen transport in skeletal muscle under conditions of high oxygen demand. , 2001, Journal of applied physiology.

[26]  Alberto Mantovani,et al.  Inflammation and cancer: breast cancer as a prototype. , 2007, Breast.

[27]  Joaquin Casal,et al.  Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma , 2006, Anti-cancer drugs.

[28]  Lisa M. Coussens,et al.  Immune cells as mediators of solid tumor metastasis , 2008, Cancer and Metastasis Reviews.